Other Events ·
Anavex Life Sciences Corp. announced on September 2, 2026, that it has regained compliance with Nasdaq Listing Rule…
AVXLAnavex Life Sciences Corp.
Anavex Life Sciences Corp. announced on September 2, 2026, that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following a delinquency notification received in May 2026 due to the late filing of its Form 10-Q for the period ended March 31, 2026. The company submitted a compliance plan on July 20, 2026, and filed the outstanding quarterly reports for the periods ended March 31 and June 30, 2026, on August 28, 2026. Nasdaq confirmed the restoration of compliance, allowing Anavex's common stock to continue trading on the Nasdaq Global Select Market under the ticker AVXL without further delisting risk related to this specific filing requirement. This resolution mitigates near-term operational uncertainty regarding exchange listing status for the clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases.